About Avertix

Ross Haghighat is the Executive Chairman of Avertix. Ross is a seasoned senior executive with over three decades of experience as a serial entrepreneur, investor, venture capitalist, and Board member.

Ross has been the founder or co-founder of dozen startups, has taken 5 companies public, and has helped transform a half dozen startups from early stage to successful global businesses across multiple disciplines. His companies have raised in excess of $2 Billion and he has been a leading force that has helped to generate over $4B in shareholder value.

Ross currently serves as CEO and Chairman of Triton Systems, a leading technology incubator with a private equity investment arm, He is the CEO of BioPlus Acquisition Corp. (Nasdaq: BIOS), a Nasdaq listed blank check company; is on the Board of Directors at Chinook Therapeutics (Nasdaq: KDNY), a late clinical-stage precision medicines therapeutics company; a funding Board member of Fluence Corporation Ltd. (ASX: FLC), a leading ESG global water treatment technology company; is Chairman of the Board of FRX Innovations (TSX:FRXI). Earlier in his career he was a founding Board member of Aduro Biotech (NASDAQ: ADRO) and a co-founder of Sensera Corporation which was acquired by AbioMed (Nasdaq: ABMD).

Timothy P. Moran joined Avertix in April 2023 as President and Chief Executive Officer.

Previously, Tim served as Chief Executive Officer of Motus GI(Nasdaq: MOTS), a medical device company providing innovative endoscopic solutions for the diagnosis and management of gastrointestinal conditions, from 2018 to 2023. Earlier in his career, from 2015 to 2018, Tim was President, Americas at ConvaTec Group Plc(LON: CTEC), an international medical products and technologies company.Prior to his employment at ConvaTec, he held various leadership roles over the course of eighteen years at Covidien plc(“ Covidien”), an Irish headquartered global health care products company. Following the acquisition of Covidien by Medtronic (NYSE:MDT), Tim was named Global Vice President and General Manager of Patient Care and Safety, a division generating annual revenues exceeding $1B.

In his capacity as CEO, Tim serves on the Board of Avertix. He is also an Independent Director and Chairman of the Board at Motus GI. Tim earned a B.A. in Organizational Communication from The State University of New York at Geneseo.

Philip L. Tom joined Avertix in April 2023 as EVP and Chief Financial Officer.

Philip has over a decade of experience in finance as an investor, advisor, and operator. Most recently, Philip was Principal at Explorer Acquisitions, a serial SPAC sponsor with 7 SPAC IPOs. He’s also served as CFO for Hudson MX, an ad-tech, cloud-based SaaS media solution for commercial advertising, and sat on the investment team at Insight Partners, the global private equity firm based in New York.

He holds a B.A. from Stanford University and started his career in investment banking at Credit Suisse in New York.

Elia’s expertise includes market development, sales, acquisitions and partnerships with 25 years of experience in the electrophysiology field. He was Chief Strategy and Business Development Officer with Acutus Medical, and Vice President of Business Development and Sales with Biotronik. Elia worked with a start-up CPI, later named Guidant Corporation, which was acquired by Boston Scientific. Before he turned 32, he became a national sales leader, overseeing 400 staff and $400 million in sales revenue. Together with a core business partnership, he created a unique sales organization within a tier 3 company and grew their market share as a distant fourth player with 2% share, to an innovative growth hacker with 10% share over seven years. Elia has a BS from San Diego State University.

David has over 20 years of experience in the development and deployment of complex active cardiovascular implants. He was actively involved in the development of the Avertix Guardian™ system from the start and participated in the first-in-human implant in Brazil, and the first implants in the US and Germany.

Dave took over responsibility for the ALERTS Clinical Study in 2012 and then oversaw the analysis and reporting of efficacy and safety results for the PMA submission, including the amendment that led to FDA approval. Dave has a dozen patents related to medical devices and computer networking technologies.

Prior to Avertix, Dave was a Director at Corente, Inc. (formally OpenReach), a leader in managed secure networks. At OpenReach, Dave managed the provisioning and support of networks in 40 countries. Before joining Corente, Dave spent 15 years at AT&T Bell Laboratories. During that time, Dave worked within the R&D team that created Ethernet over twisted pair wire. Dave traveled to over 44 countries during this period to support and troubleshoot network problems for AT&T and NCR. Prior to AT&T, Dave worked in R&D for Perkin Elmer Corporation on some of the world’s first 32-bit minicomputers, used to power state of the art military simulators. Dave’s first job after graduating from The Catholic University of America was in the Inhalation Toxicology Labs of Hazleton Laboratories in Reston, Virginia. This lab was the setting for the best seller “The Hot Zone” which chronicled the early discoveries associated with the ebola virus.

Sasha has 30 years of experience in statistical/ algorithmic assessment of biological signals, with a focus on clinical translation.

As Chief Scientific Officer, Sasha has been responsible for managing presentation and publication of ALERTS trial data, design and conduct of ALERTS post-approval studies, and conducting economic and quality-of-life assessment of the Guardian technology. Sasha has led Avertix’s market access efforts including obtaining a Transitional Pass Through (TPT) payment from CMS in 2021. Sasha has successfully obtained NIH grant funding (Phase I/II/IIb) for R&D related to the Company’s next generation products and assisted in company innovation including management of its IP portfolio. Sasha’s background in clinical translation of medical technology includes creation of a neuroimaging-based hearing assessment technology (acquired by Bio-logic Systems Corp, now Natus) and closed-loop neurostimulation technology (licensed by Neuropace). He holds 100+ US patents and has served as an IP strategy consultant in the areas of neurostimulation, neuroimaging, wireless power transmission, renal nerve ablation, and medical wearables. He has lectured annually at University of Toronto since 2007 on commercialization of medical technology.

Sasha received a MSc. in Psychiatry from McGill University and PhD in Medical Science from University of Toronto.

As the SVP Marketing of Avertix, Holly is responsible for creating and implementing an effective marketing strategy to support the Company’s vision of transforming lives by improving physician and patient engagement in healthcare management. She promotes the Company’s exceptional product innovation and purpose-driven initiatives by building marketing programs and thought leadership, and by establishing and maintaining strong global brand recognition.

Holly has over two decades of experience in worldwide marketing across industries including medical devices, automotive, and wellness. Her expertise includes product branding and marketing, advertising, communications, investor relations, digital and social media, and partnerships.

She was VP of Communications at Lucira Health (Pfizer) and VP of Marketing Communications at Acutus Medical. She held various ascending leadership roles in private and public companies and has lived and worked in six countries. Holly has a daughter, the joyful pinnacle of her life.

Holly has an M.B.A. from Middlebury Institute of International Studies at Monterey, California, and a B.A. in Spanish and Business from the University of Colorado at Boulder.